CRISPR Gene Therapy Shows Promise for Sickle Cell in Landmark Trial
A Phase III trial reports a 94% reduction in pain crises among patients treated with the gene-editing therapy, raising hopes for a functional cure.
By Thomas Keller9 min read
T
Thomas Keller
Science Correspondent
Thomas Keller writes about science and the natural world with a focus on climate, space exploration, and the philosophy of scientific inquiry. He previously held positions at Nature and New Scientist.
Articles by Thomas